Proton nuclear magnetic resonance spectroscopy measurements of methylene and methyl line widths in plasma: significant variations with extent of breast cancer, duration of pregnancy and aging
- PMID: 1911102
- DOI: 10.1002/nbm.1940040306
Proton nuclear magnetic resonance spectroscopy measurements of methylene and methyl line widths in plasma: significant variations with extent of breast cancer, duration of pregnancy and aging
Abstract
The composite methylene (chemical shift range 1.2-1.4 ppm) and methyl (0.8-0.9 ppm) resonances of the 1H NMR spectrum were analyzed in plasma samples from breast tumor patients, pregnant women, and healthy subjects. Using a 500 MHz NMR instrument operating at 25 degrees C, the peaks were analyzed for line width at half height and then averaged. A statistically significant difference (p less than 0.001) was found between the average (mean +/- SD) line width in the plasma samples from the 30 patients with metastatic breast cancer (34.1 +/- 5.0 Hz) and the controls matched for age and sex (38.7 +/- 4.4 Hz). In the 16 patients with localized breast cancer and the 16 with regional spread, the average line width was not different from that of matched controls. In 21 patients with benign tumor in the breast, the average line width was not different from that of matched controls. A difference in the average line width was found between 31 pregnant women in the third trimester (32.5 +/- 3.4 Hz) and their controls matched for age and sex (42.7 +/- 4.6 Hz) (p less than 0.001). The average line width was lower in the late (31.5 +/- 3.3) than in the early (34.5 +/- 2.5 Hz) part of the third trimester (p = 0.022). In 54 healthy male and 130 healthy female controls, line widths declined gradually with increasing age by decades, except in the fifth decade for the men and the sixth decade for the women.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Early changes in the 1H-NMR plasma spectrum in patients following breast surgery.Eur J Surg Oncol. 1993 Apr;19(2):115-22. Eur J Surg Oncol. 1993. PMID: 8491314
-
Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer.N Engl J Med. 1990 Apr 5;322(14):949-53. doi: 10.1056/NEJM199004053221402. N Engl J Med. 1990. PMID: 2314446 Clinical Trial.
-
Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.N Engl J Med. 1986 Nov 27;315(22):1369-76. doi: 10.1056/NEJM198611273152201. N Engl J Med. 1986. PMID: 3022146
-
The NMR blood test for cancer: current status.Cancer Cells. 1991 May;3(5):173-82. Cancer Cells. 1991. PMID: 1654067 Review.
-
Proton NMR spectroscopy of plasma lipoproteins: a marker of the immune function in cancer disease?Anticancer Res. 1994 Sep-Oct;14(5A):1839-51. Anticancer Res. 1994. PMID: 7847817 Review.
Cited by
-
Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.Breast Cancer Res Treat. 1995;36(3):287-97. doi: 10.1007/BF00713400. Breast Cancer Res Treat. 1995. PMID: 8573711
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical